Identification

Name
Lercanidipine
Accession Number
DB00528  (APRD00193)
Type
Small Molecule
Groups
Approved, Investigational
Description

Lercanidipine is a calcium channel blocker of the dihydropyridine class.

It is sold under various commercial names including Zanidip.

Structure
Thumb
Synonyms
  • Lercanidipine
  • Lercanil
Categories
UNII
V7XTJ4R0BH
CAS number
100427-26-7
Weight
Average: 611.7272
Monoisotopic: 611.299536059
Chemical Formula
C36H41N3O6
InChI Key
ZDXUKAKRHYTAKV-UHFFFAOYSA-N
InChI
InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3
IUPAC Name
3-{1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of Hypertension, management of angina pectoris and Raynaud's syndrome

Pharmacodynamics

Lercanidipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Lercanidipine is similar to other peripheral vasodilators. Lercanidipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

Mechanism of action

By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Lercanidipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

TargetActionsOrganism
AVoltage-dependent calcium channel gamma-1 subunit
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Lercanidipine.Investigational
AcebutololLercanidipine may increase the hypotensive activities of Acebutolol.Approved, Investigational
AceclofenacThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Lercanidipine.Approved, Vet Approved
Acetylsalicylic acidThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Lercanidipine.Investigational
AlclofenacThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlcuroniumLercanidipine may increase the neuromuscular blocking activities of Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Aldesleukin.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
AliskirenLercanidipine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Alminoprofen.Experimental
AlprenololLercanidipine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
Aluminium clofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Aluminium clofibrate.Experimental
AmbrisentanLercanidipine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineLercanidipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Amiloride.Approved
AminophenazoneThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Aminophenazone.Approved, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Lercanidipine.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Lercanidipine.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Lercanidipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Lercanidipine.Approved, Illicit
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Lercanidipine.Approved
Amphotericin BLercanidipine may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Lercanidipine can be decreased when combined with Amprenavir.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Amyl Nitrite.Approved
AntipyrineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Antipyrine.Approved, Investigational
AntrafenineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Antrafenine.Approved
ApalutamideThe serum concentration of Lercanidipine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Lercanidipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Lercanidipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Lercanidipine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Lercanidipine.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Lercanidipine.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Lercanidipine.Approved, Investigational
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Lercanidipine.Approved
AtazanavirThe serum concentration of Lercanidipine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Lercanidipine.Approved
AtorvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Lercanidipine is combined with Atorvastatin.Approved
AtracuriumLercanidipine may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateLercanidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilAvanafil may increase the antihypertensive activities of Lercanidipine.Approved
AzapropazoneThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Azapropazone.Withdrawn
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Azilsartan medoxomil.Approved, Investigational
BalsalazideThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Lercanidipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Lercanidipine.Illicit
BarnidipineLercanidipine may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilLercanidipine may increase the hypotensive activities of Benazepril.Approved, Investigational
BenazeprilatLercanidipine may increase the hypotensive activities of Benazeprilat.Experimental
BendazacThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Lercanidipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Lercanidipine.Withdrawn
BenorilateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Benzydamine.Approved
BepridilLercanidipine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Lercanidipine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Lercanidipine.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Lercanidipine.Approved
BezafibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Bezafibrate.Approved, Investigational
BietaserpineBietaserpine may increase the hypotensive activities of Lercanidipine.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Lercanidipine.Approved, Investigational
BimatoprostLercanidipine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Lercanidipine.Approved
BisoprololLercanidipine may increase the hypotensive activities of Bisoprolol.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Lercanidipine.Approved
BoceprevirThe serum concentration of Lercanidipine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Lercanidipine.Approved, Investigational
BosentanThe serum concentration of Lercanidipine can be decreased when it is combined with Bosentan.Approved, Investigational
BQ-123Lercanidipine may increase the hypotensive activities of BQ-123.Investigational
BretyliumLercanidipine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Lercanidipine.Approved, Investigational
BromfenacThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Lercanidipine.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Lercanidipine.Investigational
BufexamacThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Bufexamac.Approved, Experimental
BumadizoneThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Bumetanide.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Lercanidipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lercanidipine.Approved, Investigational
BupranololLercanidipine may increase the hypotensive activities of Bupranolol.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Lercanidipine.Approved
CadralazineCadralazine may increase the hypotensive activities of Lercanidipine.Experimental
Calcium AcetateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Canagliflozin.Approved
CandesartanLercanidipine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilLercanidipine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilLercanidipine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilLercanidipine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Lercanidipine can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Lercanidipine.Approved, Investigational
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Lercanidipine.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Lercanidipine.Withdrawn
CarprofenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololLercanidipine may increase the hypotensive activities of Carteolol.Approved
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Lercanidipine.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Lercanidipine.Approved, Investigational, Nutraceutical, Vet Approved
CelecoxibThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololLercanidipine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Lercanidipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Lercanidipine is combined with Cerivastatin.Approved, Withdrawn
ChlorothiazideLercanidipine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Lercanidipine.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Lercanidipine.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CicletanineLercanidipine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilLercanidipine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Lercanidipine.Approved, Investigational
CimetidineThe serum concentration of Lercanidipine can be increased when it is combined with Cimetidine.Approved, Investigational
CimicoxibThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Cimicoxib.Investigational
CiprofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Ciprofibrate.Approved, Investigational
CisatracuriumLercanidipine may increase the neuromuscular blocking activities of Cisatracurium.Approved
ClarithromycinThe serum concentration of Lercanidipine can be increased when it is combined with Clarithromycin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Lercanidipine.Approved, Investigational
ClofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Clofibrate.Approved, Investigational
ClofibrideThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Clofibride.Experimental
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Lercanidipine.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Lercanidipine.Approved
ClonixinThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Clonixin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lercanidipine.Approved
CloranololLercanidipine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe serum concentration of Lercanidipine can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Lercanidipine.Approved
CobicistatThe serum concentration of Lercanidipine can be increased when it is combined with Cobicistat.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Lercanidipine.Approved, Investigational
CrizotinibThe metabolism of Lercanidipine can be decreased when combined with Crizotinib.Approved
CryptenamineLercanidipine may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe serum concentration of Lercanidipine can be increased when it is combined with Curcumin.Approved, Investigational
CyclopenthiazideLercanidipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Lercanidipine.Approved, Investigational, Vet Approved
CyclothiazideLercanidipine may increase the hypotensive activities of Cyclothiazide.Approved
DabrafenibThe serum concentration of Lercanidipine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe metabolism of Lercanidipine can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Lercanidipine.Approved, Investigational, Withdrawn
DapagliflozinThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Lercanidipine.Approved
DarunavirThe serum concentration of Lercanidipine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Lercanidipine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
DeferasiroxThe serum concentration of Lercanidipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilLercanidipine may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe serum concentration of Lercanidipine can be increased when it is combined with Delavirdine.Approved
DeserpidineLercanidipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lercanidipine.Approved
DexamethasoneThe serum concentration of Lercanidipine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexibuprofenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Dexibuprofen.Approved, Investigational
DexketoprofenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Dexketoprofen.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Dexmedetomidine.Approved, Vet Approved
DexniguldipineLercanidipine may increase the hypotensive activities of Dexniguldipine.Experimental
DiazoxideDiazoxide may increase the hypotensive activities of Lercanidipine.Approved
DiclofenacThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineLercanidipine may increase the hypotensive activities of Diethylnorspermine.Investigational
DifenpiramideThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Difenpiramide.Experimental
DiflunisalThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Diflunisal.Approved, Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Lercanidipine.Approved, Investigational
DiltiazemThe serum concentration of Lercanidipine can be increased when it is combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Dinutuximab.Approved, Investigational
DipyridamoleDipyridamole may increase the antihypertensive activities of Lercanidipine.Approved
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Lercanidipine.Approved
DorzolamideLercanidipine may increase the hypotensive activities of Dorzolamide.Approved
DoxacuriumLercanidipine may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Lercanidipine.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Lercanidipine.Approved, Investigational
DoxycyclineThe serum concentration of Lercanidipine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Lercanidipine.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Lercanidipine.Approved, Vet Approved
DroxicamThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Droxicam.Withdrawn
DuloxetineLercanidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Lercanidipine.Approved
EfavirenzThe serum concentration of Lercanidipine can be increased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Lercanidipine.Approved
EfonidipineLercanidipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Empagliflozin.Approved
EnalaprilLercanidipine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatLercanidipine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Lercanidipine.Experimental
EnzalutamideThe serum concentration of Lercanidipine can be decreased when it is combined with Enzalutamide.Approved
EpanololLercanidipine may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Eplerenone.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Lercanidipine.Approved
EprosartanLercanidipine may increase the hypotensive activities of Eprosartan.Approved
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Lercanidipine.Approved
ErythromycinThe metabolism of Lercanidipine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololLercanidipine may increase the hypotensive activities of Esatenolol.Experimental
EsmololLercanidipine may increase the hypotensive activities of Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Etacrynic acid.Approved, Investigational
EthenzamideThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Ethenzamide.Experimental
EtodolacThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Etofenamate.Approved, Investigational
EtofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Etofibrate.Approved
EtoricoxibThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Lercanidipine can be decreased when it is combined with Etravirine.Approved
FelbinacThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Felbinac.Experimental
FelodipineLercanidipine may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Fenbufen.Approved
FenofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Fenofibrate.Approved
Fenofibric acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Fenofibric acid.Approved
FenoldopamLercanidipine may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Fenoprofen.Approved
FentiazacThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Fentiazac.Experimental
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Lercanidipine.Experimental
FeprazoneThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Feprazone.Experimental
Ferulic acidLercanidipine may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Lercanidipine.Approved, Investigational
FirocoxibThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Firocoxib.Experimental, Vet Approved
FloctafenineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FluconazoleThe metabolism of Lercanidipine can be decreased when combined with Fluconazole.Approved, Investigational
FlunixinThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Flunoxaprofen.Experimental
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Lercanidipine.Approved, Investigational, Withdrawn
FlurbiprofenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Lercanidipine.Experimental
FluvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Lercanidipine is combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Lercanidipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Lercanidipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Lercanidipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Lercanidipine.Approved
FosinoprilatLercanidipine may increase the hypotensive activities of Fosinoprilat.Experimental
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Lercanidipine.Approved, Investigational
FostamatinibFostamatinib may increase the antihypertensive activities of Lercanidipine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Lercanidipine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Lercanidipine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GallamineLercanidipine may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideLercanidipine may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GemfibrozilThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Gemfibrozil.Approved
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Lercanidipine.Approved, Investigational
GuacetisalThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Guacetisal.Experimental
GuanabenzLercanidipine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Lercanidipine.Approved
GuanazodineLercanidipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineLercanidipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
GuanoclorLercanidipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzLercanidipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanLercanidipine may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Lercanidipine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Lercanidipine.Experimental
HexamethoniumLercanidipine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Lercanidipine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Lercanidipine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Lercanidipine.Approved
HydrochlorothiazideLercanidipine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideLercanidipine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IbuprofenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Ibuproxam.Withdrawn
IcosapentThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Icosapent.Approved, Nutraceutical
IdelalisibThe serum concentration of Lercanidipine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Lercanidipine.Approved
IloprostIloprost may increase the hypotensive activities of Lercanidipine.Approved, Investigational
ImatinibThe metabolism of Lercanidipine can be decreased when combined with Imatinib.Approved
ImidaprilLercanidipine may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Lercanidipine.Approved
IndapamideLercanidipine may increase the hypotensive activities of Indapamide.Approved
IndenololLercanidipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Lercanidipine can be increased when it is combined with Indinavir.Approved
IndobufenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Lercanidipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Lercanidipine.Withdrawn
IrbesartanLercanidipine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Lercanidipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Lercanidipine.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Lercanidipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Lercanidipine.Approved, Vet Approved
IsoniazidThe metabolism of Lercanidipine can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
ItraconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Lercanidipine can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Lercanidipine.Investigational
KetoconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Lercanidipine.Approved
LacidipineLercanidipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Lercanidipine.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Lercanidipine.Approved
LatanoprostLercanidipine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Levobupivacaine.Approved, Investigational
LevodopaLercanidipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Levosimendan.Approved, Investigational
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Lercanidipine.Approved
LinezolidLinezolid may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LinsidomineLercanidipine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLercanidipine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LofexidineLercanidipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Lonazolac.Experimental
LopinavirThe serum concentration of Lercanidipine can be increased when it is combined with Lopinavir.Approved
LornoxicamThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Lercanidipine can be increased when it is combined with Lorpiprazole.Approved
LosartanLercanidipine may increase the hypotensive activities of Losartan.Approved
LovastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Lercanidipine is combined with Lovastatin.Approved, Investigational
LoxoprofenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Lercanidipine.Approved, Investigational
LuliconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Lercanidipine can be increased when combined with Lumacaftor.Approved
LumiracoxibThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanLercanidipine may increase the hypotensive activities of Macitentan.Approved
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Lercanidipine.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Lercanidipine.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Lercanidipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Lercanidipine is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Lercanidipine.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Lercanidipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Lercanidipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineLercanidipine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Lercanidipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Lercanidipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Mefenamic acid.Approved
MeloxicamThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Lercanidipine.Approved
MethoserpidineLercanidipine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Lercanidipine.Approved, Investigational
MethyclothiazideThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Methyclothiazide.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Lercanidipine.Approved
MethyldopaLercanidipine may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Lercanidipine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Lercanidipine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Lercanidipine.Approved
MetipranololLercanidipine may increase the hypotensive activities of Metipranolol.Approved
MetocurineLercanidipine may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideLercanidipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneMetolazone may increase the hypotensive activities of Lercanidipine.Approved
MetoprololThe serum concentration of Lercanidipine can be decreased when it is combined with Metoprolol.Approved, Investigational
MetyrosineLercanidipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Lercanidipine is combined with Mevastatin.Experimental
MibefradilThe serum concentration of Lercanidipine can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Lercanidipine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Lercanidipine can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Lercanidipine.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Lercanidipine.Approved, Vet Approved
MinoxidilMinoxidil may increase the hypotensive activities of Lercanidipine.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Lercanidipine.Investigational
MitotaneThe serum concentration of Lercanidipine can be decreased when it is combined with Mitotane.Approved
MivacuriumLercanidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Lercanidipine.Approved, Investigational
ModafinilThe serum concentration of Lercanidipine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilLercanidipine may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
MorniflumateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Morniflumate.Approved
MorphineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Morphine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
MuzolimineLercanidipine may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Nabilone.Approved, Investigational
NabumetoneThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Nabumetone.Approved
NadololLercanidipine may increase the hypotensive activities of Nadolol.Approved
NafcillinThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftopidilLercanidipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxoneThe serum concentration of Lercanidipine can be increased when it is combined with Naloxone.Approved, Vet Approved
NaproxenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Naproxen.Approved, Vet Approved
NebivololLercanidipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Lercanidipine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Lercanidipine can be increased when it is combined with Nelfinavir.Approved
NepafenacThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Nepafenac.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Lercanidipine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Lercanidipine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Lercanidipine.Withdrawn
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Lercanidipine.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Lercanidipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Lercanidipine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Nifedipine.Approved
NifenazoneThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Lercanidipine.Experimental
NilotinibThe serum concentration of Lercanidipine can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineLercanidipine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Lercanidipine.Approved
NitrendipineLercanidipine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Nitric Oxide.Approved
NitroaspirinThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideLercanidipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Nitrous acid.Approved, Investigational
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Lercanidipine.Approved
NS-398The therapeutic efficacy of Lercanidipine can be decreased when used in combination with NS-398.Experimental
ObinutuzumabLercanidipine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Lercanidipine.Withdrawn
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Lercanidipine.Approved, Investigational
OlaparibThe metabolism of Lercanidipine can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Lercanidipine.Approved, Investigational
OlsalazineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Olsalazine.Approved
OmapatrilatLercanidipine may increase the hypotensive activities of Omapatrilat.Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Lercanidipine.Experimental
OsimertinibThe serum concentration of Lercanidipine can be increased when it is combined with Osimertinib.Approved
OxaprozinThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Oxaprozin.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Lercanidipine.Approved
OxprenololLercanidipine may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Lercanidipine.Investigational, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Lercanidipine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Lercanidipine.Approved
PancuroniumLercanidipine may increase the neuromuscular blocking activities of Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Papaverine.Approved, Investigational
ParecoxibThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Lercanidipine.Approved
Patent BlueThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Patent Blue.Approved
PenbutololLercanidipine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Lercanidipine.Experimental
PentobarbitalPentobarbital may increase the hypotensive activities of Lercanidipine.Approved, Investigational, Vet Approved
PentoliniumLercanidipine may increase the hypotensive activities of Pentolinium.Approved
PerindoprilLercanidipine may increase the hypotensive activities of Perindopril.Approved
PerindoprilatLercanidipine may increase the hypotensive activities of Perindoprilat.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Lercanidipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Lercanidipine.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Lercanidipine.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Lercanidipine.Approved, Withdrawn
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Lercanidipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Lercanidipine.Withdrawn
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Lercanidipine.Approved
PhenylbutazoneThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Lercanidipine.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Lercanidipine.Approved
PinacidilPinacidil may increase the hypotensive activities of Lercanidipine.Approved
PindololLercanidipine may increase the hypotensive activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Pipamperone.Approved, Investigational
PipecuroniumLercanidipine may increase the neuromuscular blocking activities of Pipecuronium.Approved
PirlindolePirlindole may increase the hypotensive activities of Lercanidipine.Approved
PiroxicamThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Pirprofen.Experimental
PitavastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Lercanidipine is combined with Pitavastatin.Approved
PitolisantThe serum concentration of Lercanidipine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Lercanidipine.Withdrawn
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Lercanidipine.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Lercanidipine.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Lercanidipine.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Lercanidipine.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Lercanidipine.Approved, Vet Approved
PolythiazideLercanidipine may increase the hypotensive activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Lercanidipine.Approved, Investigational
PractololLercanidipine may increase the hypotensive activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Pramipexole.Approved, Investigational
PranoprofenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PravastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Lercanidipine is combined with Pravastatin.Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Lercanidipine.Approved
PrimidonePrimidone may increase the hypotensive activities of Lercanidipine.Approved, Vet Approved
ProglumetacinThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Proglumetacin.Experimental
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Lercanidipine.Approved, Vet Approved
PropacetamolThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Propacetamol.Approved, Investigational
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Lercanidipine.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Lercanidipine.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Lercanidipine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololLercanidipine may increase the hypotensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Proquazone.Experimental
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Lercanidipine.Approved
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Lercanidipine.Approved
QuinaprilLercanidipine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinaprilatLercanidipine may increase the hypotensive activities of Quinaprilat.Experimental
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Lercanidipine.Approved, Investigational
QuinineThe metabolism of Lercanidipine can be increased when combined with Quinine.Approved
RamiprilRamipril may increase the hypotensive activities of Lercanidipine.Approved
RamiprilatLercanidipine may increase the hypotensive activities of Ramiprilat.Experimental
RapacuroniumLercanidipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Lercanidipine.Approved
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Lercanidipine.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Lercanidipine.Approved
RescinnamineLercanidipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
RifampicinThe metabolism of Lercanidipine can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Lercanidipine can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Lercanidipine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Lercanidipine can be increased when combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
RimexoloneThe metabolism of Lercanidipine can be increased when combined with Rimexolone.Approved
RiociguatLercanidipine may increase the hypotensive activities of Riociguat.Approved
RisperidoneLercanidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Lercanidipine can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabLercanidipine may increase the hypotensive activities of Rituximab.Approved
RobenacoxibThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Robenacoxib.Experimental, Vet Approved
RocuroniumLercanidipine may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
RonifibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Ronifibrate.Experimental
RopiniroleThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Ropivacaine.Approved
RosuvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Lercanidipine is combined with Rosuvastatin.Approved
RotigotineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Sacubitril.Approved
SafinamideSafinamide may increase the hypotensive activities of Lercanidipine.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Lercanidipine.Withdrawn
SalicylamideThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Salsalate.Approved
SaprisartanLercanidipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Lercanidipine can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Sarilumab.Approved, Investigational
SC-236The therapeutic efficacy of Lercanidipine can be decreased when used in combination with SC-236.Experimental, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Lercanidipine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Lercanidipine.Approved, Investigational, Vet Approved
SelexipagLercanidipine may increase the hypotensive activities of Selexipag.Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Lercanidipine.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Lercanidipine.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Lercanidipine.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Lercanidipine.Approved
SiltuximabThe serum concentration of Lercanidipine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Lercanidipine can be increased when it is combined with Simeprevir.Approved
SimfibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Simfibrate.Experimental
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Lercanidipine.Approved
SitaxentanLercanidipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Lercanidipine.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Lercanidipine.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Lercanidipine.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Lercanidipine.Approved
SotalolThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Sotalol.Approved
SpiraprilLercanidipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Lercanidipine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Lercanidipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Sufentanil.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Lercanidipine.Approved
SulfasalazineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Sulindac.Approved, Investigational
SuprofenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Lercanidipine.Approved, Investigational
TalinololLercanidipine may increase the hypotensive activities of Talinolol.Investigational
TalniflumateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Talniflumate.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Lercanidipine.Approved, Investigational
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Lercanidipine.Approved, Investigational, Withdrawn
TelaprevirThe serum concentration of Lercanidipine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Lercanidipine can be increased when it is combined with Telithromycin.Approved
TelmisartanLercanidipine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilLercanidipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Lercanidipine.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Lercanidipine.Approved
TetrahydropalmatineLercanidipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the antihypertensive activities of Lercanidipine.Approved
ThiamylalThiamylal may increase the hypotensive activities of Lercanidipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Lercanidipine.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Lercanidipine.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Lercanidipine.Approved, Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Tiaprofenic acid.Approved
TicrynafenLercanidipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololLercanidipine may increase the hypotensive activities of Timolol.Approved
TinoridineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Tinoridine.Investigational
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Lercanidipine.Approved
TipranavirThe serum concentration of Lercanidipine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Lercanidipine can be decreased when it is combined with Tocilizumab.Approved
TocopherylquinoneLercanidipine may increase the hypotensive activities of Tocopherylquinone.Experimental, Investigational
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Lercanidipine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Tolmetin.Approved
TolonidineLercanidipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Lercanidipine.Approved
TorasemideTorasemide may increase the hypotensive activities of Lercanidipine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Lercanidipine.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Lercanidipine.Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Lercanidipine.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Lercanidipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Triamterene.Approved
TrichlormethiazideLercanidipine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Lercanidipine.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Lercanidipine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Lercanidipine.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Lercanidipine.Approved
Trolamine salicylateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Trolamine salicylate.Approved
TroleandomycinThe serum concentration of Lercanidipine can be increased when it is combined with Troleandomycin.Approved
TubocurarineLercanidipine may increase the neuromuscular blocking activities of Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Lercanidipine.Approved, Investigational
UnoprostoneLercanidipine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Lercanidipine.Investigational
ValdecoxibThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Lercanidipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Lercanidipine.Approved
VecuroniumLercanidipine may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lercanidipine.Approved
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Lercanidipine.Approved
VincamineLercanidipine may increase the hypotensive activities of Vincamine.Experimental
VoriconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Voriconazole.Approved, Investigational
XipamideLercanidipine may increase the hypotensive activities of Xipamide.Experimental
YohimbineYohimbine may decrease the antihypertensive activities of Lercanidipine.Approved, Investigational, Vet Approved
ZaltoprofenThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Lercanidipine.Approved
ZofenoprilLercanidipine may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Zomepirac.Withdrawn
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Lercanidipine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Rapolu Raji Reddy, Dasari Muralidhara Reddy, Dandamudi Satish Kumar, " NOVEL PROCESS FOR THE PREPARATION OF LERCANIDIPINE." U.S. Patent US20090227800, issued September 10, 2009.

US20090227800
General References
  1. Lin TH, Voon WC, Yen HW, Huang CH, Su HM, Lai WT, Sheu SH: Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters. Kaohsiung J Med Sci. 2006 Apr;22(4):177-83. [PubMed:16679299]
  2. Martinez ML, Lopes LF, Coelho EB, Nobre F, Rocha JB, Gerlach RF, Tanus-Santos JE: Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol. 2006 Jan;47(1):117-22. [PubMed:16424795]
  3. Agrawal R, Marx A, Haller H: Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens. 2006 Jan;24(1):185-92. [PubMed:16331117]
External Links
Human Metabolome Database
HMDB0014669
PubChem Compound
65866
PubChem Substance
46508865
ChemSpider
59276
ChEBI
135930
ChEMBL
CHEMBL250270
Therapeutic Targets Database
DAP001261
PharmGKB
PA164769058
Wikipedia
Lercanidipine
ATC Codes
C09DB08 — Valsartan and lercanidipineC08CA13 — LercanidipineC09BB02 — Enalapril and lercanidipine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHypertension,Essential2
3CompletedTreatmentHigh Blood Pressure (Hypertension)1
4CompletedTreatmentHigh Blood Pressure (Hypertension)1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Hypertension,Essential1
4RecruitingTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes1
4RecruitingTreatmentProteinuria / Renal Insufficiency,Chronic1
4Unknown StatusTreatmentHigh Blood Pressure (Hypertension) / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)1
Not AvailableRecruitingNot AvailableObesity, Morbid1
Not AvailableTerminatedTreatmentHigh Blood Pressure (Hypertension) / Microvascular Angina1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP6.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000156 mg/mLALOGPS
logP6.42ALOGPS
logP6.41ChemAxon
logS-6.6ALOGPS
pKa (Strongest Basic)9.36ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area113.69 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity177.85 m3·mol-1ChemAxon
Polarizability65.78 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9474
Blood Brain Barrier-0.9611
Caco-2 permeable-0.7039
P-glycoprotein substrateSubstrate0.9085
P-glycoprotein inhibitor IInhibitor0.9132
P-glycoprotein inhibitor IIInhibitor0.8957
Renal organic cation transporterNon-inhibitor0.7439
CYP450 2C9 substrateNon-substrate0.8448
CYP450 2D6 substrateNon-substrate0.8924
CYP450 3A4 substrateSubstrate0.7579
CYP450 1A2 substrateInhibitor0.6321
CYP450 2C9 inhibitorInhibitor0.7247
CYP450 2D6 inhibitorInhibitor0.5933
CYP450 2C19 inhibitorInhibitor0.7625
CYP450 3A4 inhibitorInhibitor0.5715
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7709
Ames testNon AMES toxic0.5517
CarcinogenicityNon-carcinogens0.668
BiodegradationNot ready biodegradable0.9895
Rat acute toxicity2.8614 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5761
hERG inhibition (predictor II)Non-inhibitor0.6908
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Nitrobenzenes / Dihydropyridinecarboxylic acids and derivatives / Nitroaromatic compounds / Aralkylamines / Dicarboxylic acids and derivatives / Vinylogous amides / Methyl esters / Enoate esters / Trialkylamines / Amino acids and derivatives
show 9 more
Substituents
Diphenylmethane / Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Nitroaromatic compound / Dihydropyridine / Aralkylamine / Dicarboxylic acid or derivatives / Hydropyridine / Methyl ester / Enoate ester
show 28 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only...
Gene Name
CACNG1
Uniprot ID
Q06432
Uniprot Name
Voltage-dependent calcium channel gamma-1 subunit
Molecular Weight
25028.105 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Burnier M, Pruijm M, Wuerzner G: Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):981-7. doi: 10.1517/17425250903085135. [PubMed:19619074]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:22